This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In a rapidly transforming pharmaceutical landscape, securing market access remains paramount. Looking ahead in 2025, several pivotal trends are set to redefine strategies for manufacturers and industry stakeholders. Source: Pharm Exec , January 31, 2025
senators sent letters to five telehealth companies that offer care through direct-to-consumer portals from pharmaceuticalmanufacturers Pfizer and Eli Lilly, interrogating their financial relationships , STAT tells us. Telehealth companies that prescribe a range of medications have not been held to the same standards.
To address growing demand from the pharmaceutical industry, Asahi Kasei has launched a new division, Asahi Kasei Life Science, effective from 1 April 2025. The new structure is designed to unify its bioprocess businesses and streamline services offered to pharmaceutical partners across drug development and manufacturing.
Structuring patient assistance programs as independent non-profit foundations helps pharmaceuticalcompanies reduce regulatory and legal exposure while allowing for more holistic, patient-centered support. Lastly, PAPs that are directly managed by pharmaceuticalcompanies may also struggle with public image issues.
Based on the new cost estimates, pharmaceuticalmanufacturers in Finland alone will be required to fund 280816 million of these expenses, The directive , enforced on 1 January 2025, imposes an extended manufacturer responsibility on the removal of micro-pollutants from wastewaters.
What are the top 3 trends that defined pharma manufacturing in India and globally in 2024? In 2024, the pharmaceuticalmanufacturing landscape underwent transformative changes, driven by technological innovations, regulatory adaptations, and evolving global demands.
Fast-Tracking the Future Nicholas Saraceno, Editor ; Don Tracy, Associate Editor April 25th 2025 Podcast Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework. Serialization 2.0:
The first industrial-scale pharmaceuticalmanufacturing facility for production of lead-212-based radioligand therapies has been inaugurated. The company hopes to produce this number tenfold by the end of 2030. billion.
GlobalData Healthcare June 19, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The oligonucleotide market is well-positioned to drive the next wave of personalised treatment. billion from 2021 to 2025 year-to-date. Credit: Kateryna Kon via Shutterstock. ASOs accounted for more than half ($3.54
Over the next few years, there are virtually no aspects of pharmaceuticalmanufacturing processes that will not be changed by artificial intelligence (AI). Ensuring that AI systems meet regulatory requirements for pharmaceuticalmanufacturing is essential The complexity of AI models presents another challenge.
CDMO Live is set to take place on 7-8 May 2025 at Rotterdam’s World Trade Center, bringing together key decision-makers in pharmaceutical outsourcing. The demand for outsourcing in pharmaceuticalmanufacturing has grown significantly, with nine out of ten biotechnology companies now depending on contract partners for production.
They may keep or pass through a percentage of prescription drug rebates paid by pharmaceuticalcompanies in return for placing their drugs on the plan’s formulary (list of preferred drugs). Other drug sales-related incentive payments from drug manufacturers to the PBM may not be disclosed or passed through. billion by 2025.
The Pharmaceutical Export Promotion Council of India (PHARMEXCIL) announces its renewed commitment to strengthening the strategic partnership between India and the United Arab Emirates (UAE) in the pharmaceutical sector.
24 Hours in the Hub Still Matters More June 16, 2025 By Chris Dowd, ConnectiveRx Commentary Article Pharmaceutical Commerce Pharmaceutical Commerce - June 2025 Volume 20 Issue 3 Doubling down on patient access and support fundamentals will win out over Washington’s next move. Chris Dowd Key Takeaways Speed is Critical.
How Recent Executive Orders Impact the Drug Pricing Landscape Nicholas Saraceno, Editor May 30th 2025 Podcast Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.
Being that TekniPlex Healthcare is indirectly involved with self-injectable devices, their prominence has brought various challenges for pharmaceuticalcompanies to overcome, including the evolution of meds. June 12, 2025. Accessed June 18, 2025. How the Rise in Self-Injectables Is Impacting PharmaceuticalManufacturing.
Source: [link] Demonstrating value Pharmaceuticalcompanies are expected to go beyond simply proving that their treatments work they need to show that their products provide real, measurable benefits for both patients and healthcare systems. How Does the HEOR Model Work for PharmaceuticalCompanies?
Indian pharmaceuticalcompanies supply more than 60 per cent of global demand for vaccines and over 40 per cent of generic medicines consumed in the United States (2). For instance, India’s role as a major supplier of COVID-19 vaccines underscored its capabilities in high-volume sterile manufacturing (4). and EU markets.
Increased API costs may force some manufacturers to reduce output or exit the market entirely, reducing competition and potentially driving price inflation. For branded pharmaceuticalcompanies, the impact may be less immediate due to their larger profit margins. Internet] Beckers Hospital Review 2025. Internet] Reuters.
Robert Barrie June 11, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Drugmakers have poured billions of dollars into pharma manufacturing facilities across the US as they adapt to macroeconomic pressures. Conversely, foreign manufacturing plants will be subject to increased inspection fees.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content